TRIM-edicine, Inc.
↗Columbus, Ohio, USA
TRIM-edicine is a privately held biotechnology company focused on developing novel protein therapeutics for regenerative medicine. The company's core technology is centered on the TRIM (tripartite motif) family of proteins, specifically MG53 (TRIM72), which plays a vital role in cell membrane repair and tissue regeneration.
Founded as a university spin-off from Rutgers and Ohio State University, TRIM-edicine targets unmet medical needs in areas such as acute kidney injury, muscular dystrophy, wound healing, and myocardial infarction. The company utilizes recombinant human protein technology to mimic natural repair mechanisms, offering non-cell-based therapeutic options for chronic and acute tissue damage.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Under $1M
Founded:2008
Ownership:private
Status:operating
FUNDING
Stage:Grant / Series A
Total Raised:$10M+
Investors:National Institutes of Health (NIH), U.S. Department of Health and Human Services (HHS), Global Cardiovascular Innovation Center, Ohio State Innovation Foundation
PIPELINE
Stage:Preclinical
Lead Drug Stage:IND-Enabling / Phase 1 Ready
Modalities:Recombinant protein, Synthetic peptide
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:The Ohio State University, Rutgers University, Robert Wood Johnson Medical School
COMPETITION
Position:Niche Player
Competitors:Mesoblast, Sarepta Therapeutics, Solid Biosciences, Capricor Therapeutics
LEADERSHIP
Key Executives:
Changhua Qiu - CEO
Jianjie Ma - Founder & President
Tao Tan - VP of R&D
Scientific Founders:Dr. Jianjie Ma
Board Members:William T. Abraham (SAB), Vincent Guacci (Advisor)
LINKS
Website:trim-edicine.com
Crunchbase:Crunchbase Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with TRIM-edicine, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.